Insights

Gathering insights about Lyda…

Similar companies to Lyda

Lyda Tech Stack

Lyda uses 8 technology products and services including Lucky Orange, WordPress, Plupload, and more. Explore Lyda's tech stack below.

Lucky Orange
Analytics
WordPress
Content Management System
Plupload
Data Management
MySQL
Database
Lenis
Javascript Libraries
Cloudflare Bot Management
Security
Google Analytics
Web Analytics
Adobe Fonts
Web Fonts

Media & News

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company's partner in Canada for the development and commercialization of NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe), has received approval from Health Canada to market NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease. Commercial launch for NILEMDO is expected in Q2 2026.
Nov 18, 2025 | www.globenewswire.com
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial
RAHWAY, N.J.--(BUSINESS WIRE)--Merck's Enlicitide, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with HeFH in Phase 3 CORALreef HeFH Trial.
Nov 09, 2025 | www.businesswire.com
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
RAHWAY, N.J.--(BUSINESS WIRE)--Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial.
Nov 08, 2025 | www.businesswire.com
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models
Oct 09, 2025 | www.globenewswire.com
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C
MUNICH, Germany--(BUSINESS WIRE)--Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal.
Aug 30, 2025 | www.businesswire.com
Daiichi Sankyo Announces the Development of a Fixed-Triple Combination Lipid-Lowering Tablet to Address Persistent Gaps in the Management of Elevated LDL-C
MUNICH, Germany--(BUSINESS WIRE)--Daiichi Sankyo Europe is pleased to announce the development of a fixed-triple oral combination lipid-lowering tablet of bempedoic acid, ezetimibe, and different doses of a statin, with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.i ii “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination with different doses of a statin, will make it easier for physicians to ta.
Aug 30, 2025 | www.businesswire.com
REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C
THOUSAND OAKS, Calif. , Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to include adults at increased risk for major adverse cardiovascular events (MACE) due to uncontrolled low-density lipoprotein cholesterol (LDL-C), commonly known as 'bad cholesterol.
Aug 25, 2025 | www.prnewswire.com

Lyda's Email Address Formats

Lyda uses at least 2 format(s):

Lyda Email Formats	Example	Percentage
First@lydafire.com	John@lydafire.com	90%
Last@lydafire.com	Doe@lydafire.com	10%

Frequently Asked Questions

Where is Lyda's headquarters located?

Lyda's main headquarters is located at 2300 Windy Ridge Pkwy SE Suite 1140N Atlanta, Georgia 30339 US. The company has employees across 3 continents, including North AmericaAsiaEurope.

What is Lyda's phone number?

You can contact Lyda's main corporate office by phone at

+1-404-549-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Lyda's stock symbol?

Lyda is a publicly traded company; the company's stock symbol is LDL.

What is Lyda's official website and social media links?

Lyda's official website is lyda.com and has social profiles on LinkedIn.

What is Lyda's NAICS code?

Lyda's NAICS code is 511 - Publishing Industries (except Internet).

How many employees does Lyda have currently?

As of October 2025, Lyda has approximately 31 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Founder & Ceo: H. L.Creative Director, Design: A. H.Marketing Director: A. A.. Explore Lyda's employee directory with LeadIQ.

What industry does Lyda belong to?

Lyda operates in the Book and Periodical Publishing industry.

What technology does Lyda use?

Lyda's tech stack includes Lucky OrangeWordPressPluploadMySQLLenisCloudflare Bot ManagementGoogle AnalyticsAdobe Fonts.

What is Lyda's email format?

Lyda's email format typically follows the pattern of First@lydafire.com. Find more Lyda email formats with LeadIQ.

When was Lyda founded?

Lyda was founded in 2003.

Lyda

Q: What is Lyda's official website and social media links?

Lyda's official website is lyda.com. Lyda has social profiles on LinkedIn.

Q: How many employees does Lyda have currently?

Lyda has approximately 31 employees.

Q: What technology does Lyda use?

Lyda's tech stack includes cdnjs, oEmbed, mOxie, Site Kit, Priority Hints.

Book and Periodical PublishingGeorgia, United States11-50 Employees

We’re Lyda, a studio built for motion, grounded in design. We partner with teams building what’s next. Our work helps them connect through motion that’s fast and built to perform. From product and software demos to live stage moments, we bring ideas to life with precision and intent.

Company Overview

Headquarters: 2300 Windy Ridge Pkwy SE Suite 1140N Atlanta, Georgia 30339 US
Phone number: +1-404-549-****
Website: lyda.com
Stock Symbol: LDL
NAICS Code: 511 - Publishing Industries (except Internet)
Founded: 2003
Employees: 11-50

Media & News

Funding & Financials

$25M$50M
Lyda's revenue is estimated to be in the range of $25M$50M

Funding & Financials

$25M$50M
Lyda's revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Lyda

Tyco SimplexGrinnell

Johnson Controls

Siemens

Edwards Vacuum

Honeywell

Tyco Integrated Security

Lyda Tech Stack

Media & News

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C

Daiichi Sankyo Announces the Development of a Fixed-Triple Combination Lipid-Lowering Tablet to Address Persistent Gaps in the Management of Elevated LDL-C

REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C

Lyda's Email Address Formats

Frequently Asked Questions

Where is Lyda's headquarters located?

What is Lyda's phone number?

What is Lyda's stock symbol?

What is Lyda's official website and social media links?

What is Lyda's NAICS code?

How many employees does Lyda have currently?

What industry does Lyda belong to?

What technology does Lyda use?

What is Lyda's email format?

When was Lyda founded?

Lyda

Company Overview

Media & News

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?